《大行》里昂升翰森制药(03692.HK)目标价至42元 料明年多种新药上市可支持盈利增长

阿斯达克财经
Jul 27

里昂发表研究报告指,翰森制药(03692.HK) 作为香港上市生物医药股中创新药收入占比最高的公司,2025年展现创新药稳步推进与对外授权强劲的平衡增长,预期在创新药持续放量带动下,今年上半年收入可录得双位数增长,但由于研发开支同时增加,预料中期纯利只有单位数增幅。该行维持2026至2028年盈利预测不变,目标价由40元升至42元,维持“跑赢大市”评级,预期翰森明年将有5款新药获批上市,包括B7-...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10